Diego A. Díaz García, Medical Oncologist , CEO and Founder at CánCare, shared an article on X:
“HER3: from understudy to key target.
Once overlooked, HER3 is now gaining ground in cancer therapy. New strategies including ADCs & bispecifics show promise—like FDA-approved Zenocutuzumab for NRG1+ NSCLC & pancreatic cancer.
This article offers an essential overview of:
- HER3 biology, mutations, and expression in tumors.
- Its role in therapy resistance and immune interactions.
- Emerging HER3-directed therapies and their potential across cancer types.”
Emerging importance of HER3 in tumorigenesis and cancer therapy.
Authors: Joan T. Garrett, Salomon Tendler, Wasim Feroz, Mary Kate Kilroy, Helena Yu.
You can read the Full Article on Journal of Nature Reviews Clinical Oncology.
More posts featuring Diego A. Díaz García.
